Protective effects of Pt-N-C single-atom nanozymes against myocardial ischemia-reperfusion injury

Tianbao Ye, Cheng Chen, Di Wang, Chengjie Huang, Zhiwen Yan, Yu Chen, Xian Jin (), Xiuyuan Wang (), Xianting Ding () and Chengxing Shen ()
Additional contact information
Tianbao Ye: Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Cheng Chen: Tongji University
Di Wang: Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Chengjie Huang: Shanghai Jiao Tong University
Zhiwen Yan: Youth Science and Technology Innovation Studio of Shanghai Jiao Tong University School of Medicine
Yu Chen: Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Xian Jin: Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Xiuyuan Wang: Fudan University
Xianting Ding: Shanghai Jiao Tong University
Chengxing Shen: Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Nature Communications, 2024, vol. 15, issue 1, 1-19

Abstract: Abstract Effective therapeutic strategies for myocardial ischemia/reperfusion (I/R) injury remain elusive. Targeting reactive oxygen species (ROS) provides a practical approach to mitigate myocardial damage following reperfusion. In this study, we synthesize an antioxidant nanozyme, equipped with a single-Platinum (Pt)-atom (PtsaN-C), for protecting against I/R injury. PtsaN-C exhibits multiple enzyme-mimicking activities for ROS scavenging with high efficiency and stability. Mechanistic studies demonstrate that the excellent ROS-elimination performance of the single Pt atom center precedes that of the Pt cluster center, owing to its better synergistic effect and metallic electronic property. Systematic in vitro and in vivo studies confirm that PtsaN-C efficiently counteracts ROS, restores cellular homeostasis and prevents apoptotic progression after I/R injury. PtsaN-C also demonstrates good biocompatibility, making it a promising candidate for clinical applications. Our study expands the scope of single-atom nanozyme in combating ROS-induced damage and offers a promising therapeutic avenue for the treatment of I/R injury.

Date: 2024
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
https://www.nature.com/articles/s41467-024-45927-3 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-45927-3

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-024-45927-3

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().